John P. Nicholson

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD.

Vaxess Technologies, Inc. provides global vaccine access distribution services. It develops a pipeline of next-generation MIMIX therapies. The firm provides MIMIX oncology and MIMIX infectious disease. The company was founded by Patrick Ho, David Kaplan, Kathryn Kosuda, Fiorenzo Omenetto, Michael Schrader and Livio Valenti in 2012 and is headquartered in Cambridge, MA.

Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA.

Wyeth Canada ULC manufactures and distributes pharmaceutical products. The company markets products in the areas of women's health care, neuroscience, musculoskeletal therapy, transplantation and immunology, hemophilia, and vaccines. It was founded in 1907 and is headquartered in Markham, Canada.

International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY.